Key Highlights

  • Third-quarter net product Revenue came to USD 197.6 million, the company's first sales of a product, after RASONQUE won FDA approval in August.
  • The net loss expanded to USD 407.5 million, or USD 1.90 per share, up from USD 305.2 million, or USD 1.61 per share, a year earlier, as launch costs climbed.
  • Research and development spending rose 59% to USD 417.1 million, and selling, general and administrative costs jumped 191% to USD 153.3 million.
  • Cash, cash equivalents and marketable securities reached USD 3.7 billion at September 30, 2026, versus USD 2.0 billion at year-end 2025.

RASONQUE Approval Turns Into First Product Revenue

Revolution Medicines (NASDAQ:RVMD) lodged its Quarterly Report on November 4, 2026, for the three months ending September 30. In August 2026 the FDA cleared RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who had at least one earlier systemic treatment or who cannot take multiagent therapy. Net product revenue reached USD 197.6 million this quarter, versus nothing in the prior-year quarter, and cost of sales was only USD 0.3 million. Sales are concentrated, since two customers represented 71% and 28% of the total. Inventory Capitalization began with approval, which means Manufacturing costs incurred before that date were booked as Research and Development expense.

Spending Build-Out Pushes the Quarterly Loss to USD 407.5 Million

The company is building RAS(ON) inhibitors, a family aimed at tumors caused by RAS mutations, and it also has zoldonrasib and elironrasib in development. Operating loss increased to USD 373.1 million from USD 315.3 million. Research and development grew to USD 417.1 million owing to larger trial and manufacturing bills, including pre-launch materials expensed before approval. Selling, general and administrative costs reached USD 153.3 million on commercial activity, headcount and Equity compensation. Below the operating line, interest expense increased to USD 33.8 million, and a USD 40.7 million rise in the Warrant liability, linked to a higher share price, was recorded as a charge. Interest income of USD 37.8 million offset part of that. Over nine months, the net loss came to USD 1.51 billion, or USD 7.24 per share (calculated from USD 1,505.6 million).

USD 3.7 Billion of Liquidity, a Term Loan Draw and Royalty Choices

Cash, cash equivalents and marketable securities total USD 3.7 billion, which management believes can finance planned operations for a minimum of 12 months. In October 2026, after the August approval, Revolution Medicines (NASDAQ:RVMD) took a first USD 250.0 million term loan Tranche and paid USD 5.0 million upfront. It declined a third tranche from Royalty Pharma (NASDAQ:RPRX) that could have supplied up to USD 250.0 million in return for added royalty payments. At-the-market sales produced USD 271.9 million gross on 2,070,899 shares across nine months. October also brought a clinical trial collaboration with Bristol-Myers Squibb (NYSE:BMY) for a bispecific antibody. Main risks cover the launch trajectory, pricing and reimbursement, Supply and rising spending.

Where Things Stand

Partly. Revolution Medicines (NASDAQ:RVMD) booked USD 197.6 million in the part of the quarter after approval, though two customers made up 99% of it (calculated). The filing does not say how much was initial stocking, so it is not yet a measure of steady demand. The loss still widened to USD 407.5 million as research and commercial costs rose. Next markers are fourth-quarter sales trends, the customer mix, expense growth, the drawn term loan and progress across the wider RAS(ON) pipeline.